The U.S. Food and Drug Administration has declined to approve Camurus' drug for the treatment of a rare hormonal disorder due ...

The regulator cited deficiencies at a third-party manufacturing facility. Camurus is seeking approval for its ...

The FDA issued a complete response letter (CRL) to Camurus, dealing a setback to the Swedish drugmaker’s efforts to bring its ...

The FDA handed a CRL to the Swedish biotech Camurus for its hormone disorder therapy over “facility-related deficiencies” at ...

CAM2029 is a novel depot formulation of octreotide, a somatostatin analogue, administered subcutaneously once monthly.

In a summary of current health news: the CDC investigates bird flu in Washington, David Joyner becomes CVS CEO, China tackles ...

In a phase III trial of adults with type 2 diabetes with heart disease and/or chronic kidney disease, oral semaglutide ...

Jefferies analyst Brian Balchin maintained a Buy rating on Camurus AB (CAMRF – Research Report) today and set a price target of ...

Munters Group AB posted the largest decline among large stocks during the session, plunging 11.0%, followed by Camurus AB shares, which declined 9.8%. Shares of Lifco AB Series B fell 5.8%.

**NM signifies a non meaningful value. A dash signifies the data is not available.

The poll showed that voters have a dim view of the state of the economy and immigration. United Statescategory With polls tight, US election campaigns target overseas voters 2:23 PM UTC United ...

The U.S. secretary of state, visiting Israel, said the killing of Hamas’s leader could create an opening for peace, and he pushed the Israeli prime minister to allow more aid into Gaza. The move ...